Research and informational content only. Not medical advice. Many peptides discussed on this site are not approved for human use.
MOTS-c
Research PeptideAlso known as: MOTS-C · MOTSc · Mitochondrial open reading frame of the 12S rRNA-c · Mitochondrial-Derived Peptide MOTS-c
Animal Only
The interventional evidence base is animal-only. The evidence is limited to animal and in vitro studies for native MOTS-c. The CB4211 analog evaluation tested a modified molecule, not the native peptide, and did not meet its liver-fat efficacy endpoint (MRI-PDFF: −5.03% CB4211 vs −4.88% placebo). All mechanistic and interventional evidence derives from mouse models and cell culture. A material commercial conflict affects essentially every foundational study: Pinchas Cohen (USC; CohBar co-founder, stockholder, board member) and Changhan David Lee (USC; CohBar consultant, shareholder) are co-authors on nearly all the seminal discovery and follow-on papers. CohBar develops MOTS-c analogs commercially. Independent replication by unaffiliated groups is limited to observational contexts.
CB4211 is not native MOTS-c
The most commonly cited 'MOTS-c clinical data' online is actually data from CB4211, a chemically modified analog developed by CohBar Inc. (the commercial entity founded by the USC research network that discovered MOTS-c) with altered pharmacokinetics and different structure from the native peptide. CB4211 evaluation did not meet its primary MRI-PDFF liver-fat efficacy endpoint (−5.03% CB4211 vs −4.88% placebo). The evidence for native MOTS-c is limited to animal and in vitro studies. When you see a source cite 'the MOTS-c trial data,' check whether it refers to CB4211 or to native MOTS-c, the distinction is frequently elided and it is the single most important disambiguation in this literature.
The MOTS-c network's own analog evaluation did not separate from placebo on its primary efficacy endpoint
The only analog-level interventional evaluation in the entire MOTS-c literature, CohBar's study of CB4211 in an obese NAFLD model, reported primary MRI-PDFF liver-fat reduction of −5.03% in CB4211 vs −4.88% in placebo. Not meaningfully different. This is the research network's own commercial entity (CohBar; co-founded by Pinchas Cohen, one of the original MOTS-c discoverers) testing its lead analog, and the primary efficacy outcome failed to separate from placebo. Liver enzymes (ALT −25%, AST −17%) did improve vs placebo, and tolerability met the study endpoint, which is why the press release was titled 'Positive Topline Results', but the primary efficacy question was not answered affirmatively. Anyone citing MOTS-c's therapeutic potential for metabolic / liver disease should also cite this result. It is the closest analog read-out the field has for this target, and it did not work as hoped.
For laboratory research use only. Not for human or animal consumption.
Evidence Tier
Animal Only
Mol. Weight
2174.6 Da
Last Reviewed
Apr 22, 2026
Claimed benefits by evidence tier
Column header colour matches the tier
Animal Only8
- Reduces obesity / body weight
- Exercise mimetic / physical-performance enhancement
- Improves bone density / prevents osteoporosis
- Cardiovascular protection / prevents heart failure
- Neuroprotection / cognitive enhancement
- Anti-aging / longevity extension
- Prevents or treats type 2 diabetes
- Anti-cancer effects
About this peptide
Plain English
When your cells make energy, the tiny structures responsible (mitochondria) don't just produce fuel, they also send out chemical signals. MOTS-c is one of those signals. It's a very small protein, only 16 amino acids long, that travels from your mitochondria to your cell's nucleus and into your bloodstream. Researchers are interested in it because it seems to improve the way the body handles blood sugar, may protect muscles as you age, and rises in the blood after exercise, which is why some have called it an "exercise mimetic." The hype outpaces the evidence. Most of what we know comes from mouse studies. Observational data in humans confirms that circulating MOTS-c levels are lower in people with type 2 diabetes and decline with age, but all interventional evidence is from rodent models and cell culture. A modified analog called CB4211, not native MOTS-c, was tested in a small preclinical-to-drug-development study and did not meet its primary liver-fat efficacy endpoint.
Technical
MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded by a short open reading frame nested within the MT-RNR1 (12S rRNA) gene of the mitochondrial genome, a rare example of a mitochondrially-encoded bioactive peptide. Upon synthesis in mitochondria, MOTS-c translocates to the nucleus under metabolic stress, where it modulates nuclear gene expression (particularly genes involved in glucose metabolism and proteostasis), representing a retrograde mitochondria-to-nucleus signaling axis. Its primary characterised metabolic mechanism involves inhibition of the folate cycle and de novo purine biosynthesis in skeletal muscle, leading to intracellular accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a known endogenous AMPK activator, AMPK activation then drives glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while suppressing gluconeogenesis. Observational studies show circulating MOTS-c levels are inversely correlated with age and with metabolic disease markers (best established in T2DM via a 2024 meta-analysis, n=602). An Asian-specific mitochondrial variant m.1382A>C (rs111033358) produces a K14Q substitution in MOTS-c associated with increased T2DM prevalence in males in a meta-analysis of approximately 27,500 subjects, a sex-dimorphic genetic association with meaningful implications for interpreting baseline MOTS-c biology across populations. CRITICAL: interventional evidence is limited to animal models and in vitro studies. The only analog-level evaluation in the MOTS-c development lineage tested CB4211, a modified analog developed by CohBar Inc. (the commercial entity founded by the research network that discovered MOTS-c), not the native peptide, and did not meet its primary MRI-PDFF liver-fat efficacy endpoint.
Mechanism of action
Folate-cycle inhibition → AICAR accumulation → AMPK activation
In skeletal muscle and cultured cells, MOTS-c inhibits enzymes in the folate cycle and the downstream de novo purine biosynthesis pathway. This causes intracellular accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator. AMPK activation increases glucose uptake and fatty acid oxidation, promotes mitochondrial biogenesis, and inhibits gluconeogenesis, the canonical metabolic-adaptation cascade. This is the central mechanism framed by Lee 2015 and the basis for the WADA S4.4.1 (AMPK Activators) classification. The full AMPK cascade has been characterized in mouse models and cell culture; it has not been directly demonstrated with exogenous MOTS-c administration beyond those preclinical settings.
Mitochondria-to-nucleus retrograde signaling
After translation in mitochondria, MOTS-c translocates to the nucleus under metabolic stress conditions. In the nucleus it binds antioxidant response element (ARE) sites and modulates nuclear gene transcription, particularly genes governing oxidative-stress response, proteostasis, and skeletal-muscle metabolism. This makes MOTS-c one of the clearest examples of mitochondria-encoded signaling directing nuclear gene expression. Confirmed in cell studies and in mouse skeletal muscle; human in-vivo retrograde signaling has not been directly demonstrated.
RANKL-inhibited osteoclastogenesis plus TGF-β/Smad osteoblast promotion
In bone tissue (mouse models), MOTS-c inhibits RANKL-induced osteoclast differentiation via AMPK-dependent signaling, while simultaneously promoting osteoblast differentiation and type-I collagen synthesis via TGF-β/Smad pathway activation. Net effect in the ovariectomy mouse osteoporosis model: improved bone mineral density, trabecular number, and thickness. The evidence is limited to animal models.
NF-κB suppression (anti-inflammatory signaling)
MOTS-c has shown inhibitory effects on NF-κB activation in multiple cell types and mouse models, reducing pro-inflammatory cytokine expression. Proposed as a mechanism for protective effects in cardiovascular and metabolic disease models. No direct human inflammation data for exogenous MOTS-c.
Exercise-induced endogenous secretion
Acute and chronic exercise increases circulating MOTS-c in observational studies. Skeletal-muscle MOTS-c expression is higher in older vs younger subjects and higher in athletes vs sedentary controls in animal and observational work. This suggests endogenous MOTS-c participates in the physiological response to exercise, and is the basis for the "exercise mimetic" framing in academic papers. CRITICAL CAVEAT: the association is observational only, and no study has tested whether exogenous MOTS-c reproduces exercise-like effects.
Nearly all mechanistic data is from mouse models or cell culture. Mice have substantially different metabolic rate, body composition, and mitochondrial biology compared to humans. Interventional mouse studies used 5 mg/kg IP, a dose and route with no established translational equivalent. That MOTS-c levels correlate with metabolic health in observational studies is established (best-quality evidence: 2024 meta-analysis, n=602); whether exogenous MOTS-c reproduces the mouse intervention effects has not been tested with the native peptide. An additional caveat at the sub-population level: the Asian-specific mitochondrial variant m.1382A>C (rs111033358) produces a K14Q substitution in MOTS-c and is associated with increased T2DM prevalence in males in a meta-analysis of ~27,500 subjects, meaning baseline MOTS-c biology is not population-invariant, and whether exogenous MOTS-c reproducibility of effect is variant-dependent is completely unstudied.
Key studies
Independence warning: most research for this peptide originates from a single research group. Replication by independent groups is limited.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (2015)
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P · Cell Metabolism 21(3):443–454
- Participants
- No humans. C57BL/6 mice (diet-induced obesity, aged mice, ob/ob genetic); in vitro mouse muscle cell lines.
- Methodology
- Mouse intervention (IP MOTS-c injection), cell culture, molecular pathway analysis.
- Result
- MOTS-c treatment prevented diet-induced obesity, age-dependent insulin resistance, and reduced blood glucose in multiple mouse models. Mechanism: folate-cycle inhibition → AICAR accumulation → AMPK activation.
Honest read
The foundational paper, entirely preclinical. All interventional data from mouse models. The 5 mg/kg IP dose used in mice has no established translational equivalent. Corresponding authors Cohen and Lee have direct financial ties to CohBar Inc., which is developing MOTS-c analogs commercially, material conflict of interest. Highly influential paper; the interventional findings have not been tested beyond rodent models. This is the canonical example of the single-research-network pattern that dominates the MOTS-c literature.
MOTS-c peptide increases survival and decreases bacterial load in mice with LPS-induced endotoxemia / MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation (2016)
Zhai D, Ye Z, Jiang Y, Xu C, Ruan B, Yang Y, Lei X, Xiang A, Lu H, Zhu Z, Yan Z, Wei D, Li Q, Wang L, Lu Z · Biochemical and Biophysical Research Communications 476(4):412–419
- Participants
- Ovariectomized C57BL/6 mice; MOTS-c 5 mg/kg IP once daily × 12 weeks.
- Methodology
- Mouse in vivo intervention.
- Result
- MOTS-c treatment significantly improved bone mineral density, trabecular number, and trabecular thickness vs controls. RANKL-induced osteoclast differentiation inhibited via AMPK activation.
Honest read
Entirely animal. Ovariectomy mouse model is standard for osteoporosis research but translational validity to broader populations is not established. Relevant here because osteoporosis is one of the two proposed PCAC indications under review July 2026, so the mouse bone data is the primary preclinical basis for that regulatory review. The evidence is limited to this animal model.
Mitochondrial-derived peptide MOTS-c prevents the development of heart failure under pressure-overload conditions in mice (2022)
Multiple · Journal / PMID 36156853
- Participants
- Mouse pressure-overload cardiac hypertrophy model.
- Methodology
- Mouse in vivo intervention.
- Result
- MOTS-c treatment prevented heart-failure development; anti-inflammatory and antioxidant mechanisms implicated.
Honest read
Animal only. The pressure-overload model is a blunt representation of human heart-failure etiologies. No human cardiovascular intervention data.
Research timeline
- 2015
Lee, Yin, Bhargava, Cohen et al. first describe MOTS-c as a mitochondrial-derived peptide encoded by MT-RNR1. Mouse and cell studies demonstrate insulin sensitization and metabolic homeostasis improvement. Foundational paper in Cell Metabolism; all interventional data from mouse models; direct commercial COI via CohBar.
- 2016
Zhai et al. publish first MOTS-c bone study: ovariectomy mouse model shows MOTS-c prevents bone loss via AMPK-dependent osteoclast inhibition.
- 2016
Cataldo et al. review published, identifies MOTS-c as novel MDP with regulatory functions in aging and disease. Early framing of the therapeutic-potential narrative.
- 2018
First human observational studies: circulating MOTS-c lower in obese male children and adolescents; inversely correlated with insulin-resistance markers.
- 2019
Kim et al. publish small observational study in Physiological Reports, plasma MOTS-c correlates with metabolites and insulin-sensitivity markers. MOTS-c was not administered; data is correlational. All four authors have affiliations overlapping with CohBar.
- 2019
CohBar initiates a drug-development evaluation of CB4211, a MOTS-c ANALOG, NOT native MOTS-c, targeting NASH/obesity. The evaluation was temporarily suspended due to tolerability issues; an amended protocol resumed the work.
- 2020
MOTS-c shown to reduce myostatin and muscle-atrophy signaling in cell and mouse studies.
- 2021
January 2021: Reynolds et al. publish landmark Nature Communications paper, MOTS-c as exercise-induced regulator of age-dependent physical decline. Mouse intervention (doubled running capacity in aged mice; healthspan extension) plus observational correlational data (plasma MOTS-c rises with exercise). The paper does not test exogenous MOTS-c administration.
- 2021
August 2021: CohBar announces topline results for the CB4211 analog evaluation. Tolerability endpoint met; ALT reduced ~25%, AST ~17% vs placebo; primary MRI-PDFF liver-fat outcome −5.03% CB4211 vs −4.88% placebo, NOT meaningfully different. Company press release framed as 'positive topline results' despite primary efficacy endpoint not separating from placebo.
- 2022
Mouse pressure-overload heart-failure study published: MOTS-c prevents heart-failure development via anti-inflammatory and antioxidant mechanisms.
- 2023
Frontiers in Endocrinology comprehensive review of MOTS-c therapeutic potential published.
- 2024
First systematic review and meta-analysis of circulating MOTS-c in metabolic states (n=602, 7 studies) published in Diabetology & Metabolic Syndrome. Independent of USC core group, confirms lower MOTS-c in T2DM (SMD −0.89). Separately, WADA adds MOTS-c to the Prohibited List under S4.4.1 (AMPK Activators), effective January 1, 2025.
- 2024
Anti-cancer cell + mouse studies published (Advanced Science 2024) showing MOTS-c suppresses ovarian cancer via USP7/LARS1 pathway, preliminary; therapeutic framing premature.
- 2025
Experimental & Molecular Medicine publishes pancreatic-islet senescence work (rodent diabetes models). Cardiovascular and cancer research continues to expand.
- 2026
April 22, 2026, FDA removes MOTS-c (free base and acetate) from compounding Category 2 after nominator withdrawal. Removal is procedural (not a safety clearance) and does not place MOTS-c on Category 1. Separately, April 16, 2026 Federal Register notice (2026-07361) schedules MOTS-c for PCAC advisory-committee review July 23–24, 2026 under docket FDA-2025-N-6895.
What we don't know
- Pharmacokinetics of exogenously administered native MOTS-c: half-life, bioavailability, volume of distribution, and tissue distribution are all unmeasured.
- Effective preclinical-to-translational dose mapping. All interventional animal data used 5 mg/kg IP; no established translational equivalent has been derived.
- Long-term safety profile. Tolerability data exists only for the CB4211 analog over a short window. Nothing is known about chronic administration effects on immune function, endocrine feedback, organ histology, or carcinogenesis for the native peptide.
- Immunogenicity. Although MOTS-c is derived from mitochondrial DNA, exogenous synthesis and administration could trigger anti-peptide antibody responses. This is an unresolved concern.
- Oral bioavailability, almost certainly very low or zero due to GI proteolysis, as with most peptides this size. Not formally measured.
- Whether exogenous bolus dosing reproduces the nuanced mitochondria-to-nucleus signaling of endogenous MOTS-c, or simply produces uncontrolled AMPK activation.
- Potential interactions with AMPK-activating agents (e.g., metformin). Additive AMPK activation is a theoretical concern but entirely unstudied.
- Sex-specific response. The Asian-specific mitochondrial variant m.1382A>C (rs111033358; K14Q) shows male-specific T2DM association in ~27,500-subject meta-analysis; whether this translates to a sex-specific response to exogenous MOTS-c is completely unstudied.
- Whether low endogenous MOTS-c predicts benefit from exogenous administration. The biomarker-association literature is well-developed; the 'low baseline predicts benefit from supplementation' leap has not been tested in any model.
- Independent replication of core interventional findings outside the USC/CohBar network. The 2024 meta-analysis is independent but observational; interventional replication remains limited.
- Head-to-head or mechanistic comparison between native MOTS-c and CB4211. CB4211 is a modified analog with altered pharmacokinetics; whether it behaves as a functional surrogate for the native peptide or as a genuinely different compound is not characterized.
Stability & handling
- Lyophilized shelf life
- Up to 36 months from manufacture when stored correctly; typically 24 months on research-supplier COAs.
- Lyophilized storage
- Freeze below −18°C (long-term); store desiccated and away from moisture and light. Lyophilized powder reported stable at room temperature for approximately 3 weeks (vendor data; not peer-reviewed). Equilibrate sealed vials to room temperature before opening.
- Reconstitution diluents
- Sterile water, used in published stability research, Bacteriostatic water for injection (0.9% benzyl alcohol), standard for multi-dose research vials
- Reconstituted (refrigerated)
- Stable at 4°C for at least 30 days by high-resolution LC-MS (no significant methionine oxidation). Practical vendor recommendation: use within 7 days for optimal potency; for longer storage, maintain at −18°C and avoid repeated freeze-thaw cycles.
- Reconstituted (room temp)
- Mass spectrometry shows no significant degradation at 37°C over 30 days either, reasonable thermal stability relative to many peptides. Still best stored refrigerated.
- OK to refreeze
- No
- Light sensitive
- Yes, protect from light
MOTS-c-specific stability and QC considerations. (1) METHIONINE OXIDATION is the primary degradation pathway. Two Met residues (positions 1 and 6: MRWQEM...). Oxidized Met sulfoxide adds +16 Da per residue (+32 Da for double oxidation), detectable only by LC-MS; standard UV-HPLC may report oxidized and native forms as a single peak depending on chromatographic conditions. Published stability research used Xevo G2-XS Q-TOF high-resolution LC-MS to track methionine oxidation as the principal degradation metric. Red flag on a COA: HPLC purity reported without corresponding LC-MS methionine-oxidation assessment. (2) FREE BASE vs ACETATE SALT, FDA explicitly evaluates MOTS-c free base and MOTS-c acetate as distinct substances. A COA that does not specify salt form allows ambiguity about effective peptide content; acetate counterions contribute mass without pharmacological activity. Red flag: '≥98% purity' without explicit salt-form statement or separate peptide-content percentage. (3) INCORRECT MW on COA, MOTS-c free acid is ~2,174.6 Da. Some vendors list different MWs or conflate human vs mouse (identical sequences, so this is a computational error flag, not a species issue). COA-listed MW substantially different from 2,174.6 without a salt-form justification warrants scrutiny. (4) TRP AND TYR RACEMIZATION, Trp (position 3) and two Tyr (positions 8, 11) are susceptible to racemization at elevated SPPS temperatures or under prolonged coupling. D-amino-acid incorporation produces peptides with correct MW and near-identical HPLC retention but potentially different biological activity and immunogenicity. Standard RP-HPLC cannot detect racemization, requires chiral analysis. (5) AGGREGATION, short peptides can aggregate in solution at higher concentrations if improperly lyophilized or if the cake is shaken; aggregates can trigger immune responses. Visible particulates or cloudiness post-reconstitution should prompt discarding the vial.
Frequently asked questions
What exactly is MOTS-c, and why is it different from other peptides?
MOTS-c is unusual because it is encoded by mitochondrial DNA, the small, separate genome inside the cell's energy-producing structures. Almost all other peptides and proteins in the body are encoded by nuclear DNA. It was discovered in 2015 when researchers found a tiny protein-coding sequence hidden inside a gene previously thought to only code for structural RNA. This mitochondrial origin is why some researchers view it as part of a mitochondria-to-nucleus communication system and why it is classified as a mitochondrial-derived peptide (MDP). Its biology is genuinely novel; the hype around it, however, far outpaces the available clinical evidence.
Is MOTS-c an "exercise mimetic"?
With important caveats. In mice, MOTS-c doubled running capacity and restored function in aged animals. The "exercise mimetic" label comes from observational correlations between circulating MOTS-c levels and exercise in animal and in vitro studies. The evidence is limited to preclinical research. "Exercise mimetic" is academic-research framing of a research direction, not a description of a proven effect.
What is CB4211, and is it the same as MOTS-c?
CB4211 is a MODIFIED ANALOG of MOTS-c developed by CohBar Inc., a biotechnology company co-founded by Pinchas Cohen, one of the original MOTS-c discoverers. CB4211 was engineered to be more chemically stable and have improved pharmacokinetics compared to native MOTS-c, and it was evaluated in a drug-development program. CB4211 is NOT the same molecule as native MOTS-c, and results from that evaluation cannot be directly extrapolated to the native peptide. As of April 2026, no further CB4211 development has been publicly announced.
How long has MOTS-c been studied?
MOTS-c was discovered in 2015, about 11 years old as a research target. The preclinical literature is reasonably developed, with strong mechanistic work in mouse models. What is genuinely missing: any completed interventional study of native MOTS-c beyond rodent models; published pharmacokinetic data for exogenous administration; and independent replication free from the USC / CohBar commercial conflict of interest, since most foundational research originates there. As of April 22, 2026 the interventional evidence is limited to animal and in vitro studies.
Last researched: Apr 22, 2026
Get the ClearBatch Report
Bi-weekly: new peptide reference profiles, third-party-tested batches, and sourcing updates.
Two emails a month. Unsubscribe anytime.